Literature DB >> 19729488

Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion.

Erin M Conn1, Kenneth A Botkjaer, Tatyana A Kupriyanova, Peter A Andreasen, Elena I Deryugina, James P Quigley.   

Abstract

To analyze the process of tumor cell intravasation, we used the human tumor-chick embryo spontaneous metastasis model to select in vivo high (PC-hi/diss) and low (PC-lo/diss) disseminating variants from the human PC-3 prostate carcinoma cell line. These variants dramatically differed in their intravasation and dissemination capacities in both chick embryo and mouse spontaneous metastasis models. Concomitant with enhanced intravasation, PC-hi/diss exhibited increased angiogenic potential in avian and murine models. PC-hi/diss angiogenesis and intravasation were dependent on increased secretion of vascular endothelial growth factor (VEGF), since treating developing tumors with a function-blocking anti-VEGF antibody simultaneously inhibited both processes without affecting primary tumor growth. PC-hi/diss cells were also more migratory and invasive, suggestive of heightened ability to escape from primary tumors due to matrix-degrading activity. Consistent with this suggestion, PC-hi/diss cells produced more of the serine protease urokinase-type plasminogen activator (uPA) as compared with PC-lo/diss. The functional role of uPA in PC-hi/diss dissemination was confirmed by inhibition of invasion, angiogenesis, and intravasation with specific function-blocking antibodies that prevented uPA activation and blocked uPA activity. These processes were similarly sensitive to aprotinin, a potent inhibitor of serine proteases, including uPA-generated plasmin. Thus, our comparison of the PC-3 intravasation variants points to key roles for the uPA-plasmin system in PC-hi/diss intravasation, possibly via (1) promoting tumor cell matrix invasion and (2) facilitating development of VEGF-dependent angiogenic blood vessels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729488      PMCID: PMC2751560          DOI: 10.2353/ajpath.2009.090384

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  68 in total

Review 1.  Cancer metastasis: building a framework.

Authors:  Gaorav P Gupta; Joan Massagué
Journal:  Cell       Date:  2006-11-17       Impact factor: 41.582

2.  Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.

Authors:  Paul J Cozzi; Jian Wang; Warick Delprado; Michele C Madigan; Stephen Fairy; Pamela J Russell; Yong Li
Journal:  Hum Pathol       Date:  2006-07-26       Impact factor: 3.466

Review 3.  The role of the organ microenvironment in the biology and therapy of cancer metastasis.

Authors:  Isaiah J Fidler; Sun-Jin Kim; Robert R Langley
Journal:  J Cell Biochem       Date:  2007-07-01       Impact factor: 4.429

4.  Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment.

Authors:  Toru Nakamura; Isaiah J Fidler; Kevin R Coombes
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

Review 5.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis.

Authors:  Jason J Christiansen; Ayyappan K Rajasekaran
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

6.  Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.

Authors:  Shahrokh F Shariat; Claus G Roehrborn; John D McConnell; Sangtae Park; Nina Alam; Thomas M Wheeler; Kevin M Slawin
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

Review 7.  uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view.

Authors:  Bernd R Binder; Judit Mihaly; Gerald W Prager
Journal:  Thromb Haemost       Date:  2007-03       Impact factor: 5.249

8.  Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation.

Authors:  Mark A Madsen; Elena I Deryugina; Sherry Niessen; Benjamin F Cravatt; James P Quigley
Journal:  J Biol Chem       Date:  2006-04-12       Impact factor: 5.157

9.  Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors.

Authors:  Jeffrey B Wyckoff; Yarong Wang; Elaine Y Lin; Jiu-feng Li; Sumanta Goswami; E Richard Stanley; Jeffrey E Segall; Jeffrey W Pollard; John Condeelis
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

10.  Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis.

Authors:  Sai Murali Krishna Pulukuri; Jasti S Rao
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

View more
  27 in total

1.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

2.  Evaluation of metastatic and angiogenic potentials of human colon carcinoma cells in chick embryo model systems.

Authors:  M Cecilia Subauste; Tatyana A Kupriyanova; Erin M Conn; Veronica C Ardi; James P Quigley; Elena I Deryugina
Journal:  Clin Exp Metastasis       Date:  2009-10-20       Impact factor: 5.150

3.  Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9.

Authors:  Ewa Zajac; Bernhard Schweighofer; Tatyana A Kupriyanova; Anna Juncker-Jensen; Petra Minder; James P Quigley; Elena I Deryugina
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

4.  Intratumoral Cancer Cell Intravasation Can Occur Independent of Invasion into the Adjacent Stroma.

Authors:  Elena I Deryugina; William B Kiosses
Journal:  Cell Rep       Date:  2017-04-18       Impact factor: 9.423

5.  Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation.

Authors:  Erin M Bekes; Bernhard Schweighofer; Tatyana A Kupriyanova; Ewa Zajac; Veronica C Ardi; James P Quigley; Elena I Deryugina
Journal:  Am J Pathol       Date:  2011-07-08       Impact factor: 4.307

6.  Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.

Authors:  Erin M Bekes; Elena I Deryugina; Tatyana A Kupriyanova; Ewa Zajac; Kenneth A Botkjaer; Peter A Andreasen; James P Quigley
Journal:  Neoplasia       Date:  2011-09       Impact factor: 5.715

7.  Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation.

Authors:  Kasper Almholt; Anna Juncker-Jensen; Ole Didrik Lærum; Morten Johnsen; John Rømer; Leif Røge Lund
Journal:  Clin Exp Metastasis       Date:  2012-09-21       Impact factor: 5.150

8.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

9.  In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.

Authors:  B Casar; I Rimann; H Kato; S J Shattil; J P Quigley; E I Deryugina
Journal:  Oncogene       Date:  2012-12-03       Impact factor: 9.867

10.  Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination.

Authors:  Anna Juncker-Jensen; Elena I Deryugina; Ivo Rimann; Ewa Zajac; Tatyana A Kupriyanova; Lars H Engelholm; James P Quigley
Journal:  Cancer Res       Date:  2013-05-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.